



Press Release |

IBA ANNOUNCES YEAR-END RESULTS FOR 2007 DOUBLE-DIGIT GROWTH IN SALES AND RECURRING REVENUES PROPOSED FIRST DIVIDEND OF EUR 0.17 PER SHARE

Embargo until 5:40 PM (Belgian time) – March 6, 2008

Sales growth of 25.6 percent and recurring revenues of EUR 11.8 million spread across the Group's four divisions:

- IBA Molecular.** Record year for PET and SPECT cyclotrons: 19 orders logged and three new FDG production facilities opened.
- IBA Particle Therapy.** Three orders for proton therapy centers.
- IBA Dosimetry.** Launch of COMPASS, a state-of-the-art solution for quality assurance in radiotherapy.
- IBA Industrial.** International success for the Rhodotron® and the Dynamitron®, with five orders logged and entry into the petroleum cracking market.

Louvain-la-Neuve, Belgium, March 6, 2008 – IBA (Ion Beam Applications S.A.: Reuters IBAB.BR and Bloomberg IBAB.BB) announced its consolidated results today for the year ended December 31, 2007.

KEY FACTS AND FIGURES

It should be noted that net earnings for 2006 were heavily influenced by the nonrecurring positive effects of acquisition of Schering's radiopharmaceutical operations of EUR 24.7 million.

Highlights of IBA results for 2007:

- Sales of EUR 213.8 million, up 25.6 percent (30.0 percent at constant EUR/USD exchange rates).
- Recurring earnings of EUR 11.8 million, up 20.7 percent over the 2006 figure of EUR 9.8 million, despite:
 - the depreciation of the dollar (growth at constant EUR/USD exchange rates was actually 29.7 percent).
 - R&D investment to further enhance the Group's competitive edge (in 2007 R&D investment increased to EUR 7.1 million, or 8 percent of sales).
- A record equipment order book ("backlog") worth EUR 216 million, showing growth of 52% compared to the end of 2006, the completion of which will be staggered over 1 to 3 years.



Press Release |

	Dec. 31, 2007	Dec 31, 2006	Change	
	(In thousand euros)	(In thousand euros)	(In thousand euros)	(%)
Sales and service	213,849	170,257	43,592	25.6%
Recurring earnings	11,788	9,769	2,034	20.7%
Income for the period	13,930	30,006	-16,062*	-53.5%

* As a reminder of the 2006 results, EUR 30.0 million, there was an impact worth EUR 24.7 million made by the non-recurrent positive effects of the takeover of Schering's radio-pharmaceutical business

Breakdown of the year's facts and figures by business area:

RADIOISOTOPE PRODUCTION AND DISTRIBUTION

- Sales growth of 18.4 percent to EUR 78.3 million in 2007, compared with EUR 66.1 million in 2006. At constant exchange rates, growth was 27.1 percent.
- Extension of the PET (positron emission tomography) network:
 - Three FDG (fluorodeoxyglucose) production and distribution facilities opened in Europe: in Udine, Italy; Brussels, Belgium, and Dinnington, England.
 - A European radiopharmaceutical R&D and production facility opened in Fleurus, Belgium.
 - Four FDG production and distribution facilities under construction: three in Europe (in Fleurus and Ghent, Belgium, and in Guildford, England) and one the United States (in Los Angeles).
- Note: IBA's planned acquisition of 100-percent ownership of CIS Bio International (CISBIO) should add around 100 million euros to the Group's annual sales. By way of background, in May 2006 IRE (Institut National des Radioéléments, based in Fleurus, Belgium) and IBA purchased 100 percent of CISBIO from Schering AG through their RadioPharma Partners (RPP) consortium. This transaction gave IRE an 80.1-percent stake in the company and IBA, a 19.9-percent stake. Takeover from IRE should be finalized by midyear 2008.

TECHNOLOGY AND EQUIPMENT

- Sales up 30.2 percent to EUR 135.6 million in 2007, compared with EUR 104.2 million in 2006.
- Significant growth in order backlog, now at EUR 216 million.
- Proton therapy:
 - Orders for three proton therapy systems in the United States: two systems for ProCure Treatment Centers, Inc., and one for the Hampton University Proton Therapy Institute in Virginia.
 - Letter of intent signed with Arachade in early 2008 for the development of a new hadron therapy system in Caen, France. The latest advances in hadron therapy are based on using the strong biological action of carbon ion beams to treat certain tumors, such as radiation-resistant tumors, more effectively.
 - Work completed on IBA's Louvain-la-Neuve facility, increasing production capacity to eight proton therapy systems a year.


Press Release |

- IBA is now the uncontested leader in international particle therapy. Thirteen institutions in the United States, Asia, and Europe have already chosen proton therapy systems integrating IBA technology.
- Cyclotrons: Orders for 19 PET and SPECT cyclotrons in 2007, a big increase over the previous year's eight orders.
- Dosimetry: The new COMPASS dosimetry product developed by RaySearch Laboratories received 510(k) approval from the U.S. FDA in late 2007 and is now being marketed. Dosimetry sales growth of 10-plus percent is due in part to success in the Asian market.
- Electron accelerators (Rhodotron® and Dynamitron® E-beam/X-ray industrial accelerators): The year was marked by the sale of a Dynamitron® to Germany's BGS for the irradiation of plastic cables, pipes, and tubes, as well as by orders for Rhodotron® accelerators for medical device sterilization in Austria, Brazil, Japan, and Malaysia. In early 2008, IBA also logged a Rhodotron® order from PetroBeam, Inc., a U.S. technology development company in the oil services industry in which IBA has acquired a 10-percent stake with warrants allowing it to raise its holding to around 20 percent. In addition, development of the cargo screening prototype is proceeding on schedule.

GROUP

- In the summer of 2007, IBA opened a new site in Beijing, China. The new building houses a factory and offices that serve as IBA headquarters for Asia.

DISTRIBUTION OF CONSOLIDATED SALES BY BUSINESS AREA





Press Release |

RESULTS IN DETAIL

For 2007 as a whole, IBA posted sales gains of 25.6 percent compared to the same period of 2006.

	2007		2006		Change
	2007 Rates	(% of total)	2006 Rates	(% of total)	
	(In thousand euros)		(In thousand euros)		(%)
Radioisotopes	78,265	37%	66,087	39%	18.4%
Technology & Equipment	135,584	63%	104,170	61%	30.2%
Consolidated Group	213,849	100%	170,257	100%	25.6%

The USD/EUR exchange rate averaged 1.37 dollars to the euro in 2007. Compared with 1.2558 dollars to the euro a year earlier, this represents a dollar depreciation of 9.0 percent. At constant exchange rates, earnings growth would have been 30.0 percent. As in previous years, almost 50 percent of IBA's operations were influenced by the value of the U.S. dollar.

OPERATING RESULTS

Gross margin was EUR 69.9 million, up 30.9 percent over 2006. As a percentage of sales, gross margin increased to 32.7 percent in 2007, compared with 31.3 percent in 2006. This growth was due primarily to an improvement in profit margins in the Radioisotope Production and Distribution business area.

Sales and marketing costs (up 33.4 percent over 2006) and research and development costs (up 71.2 percent) reflect strategic investment in these areas, especially proton therapy, as well as a change in scope due to the absorption of operations purchased from Schering in 2006.

IBA reported recurring earnings for 2007 of EUR 11.8 million compared with EUR 9.8 million a year earlier—an increase of 20.7 percent. This represents an increase of 29.7 percent at constant EUR/USD exchange rates.

OTHER NONRECURRING INCOME AND EXPENSE

Nonrecurring results for the first half of 2007 showed a charge of EUR 4.7 million, due primarily to litigation expenses and provisions, including expenses and provisions in connection with ending litigation with Optivus; reversal of depreciation on previously depreciated plant, and decreases in the value of current assets.



Press Release |

FINANCIAL RESULTS

IBA posted a financial loss of EUR 0.5 million in 2007, compared with a profit of EUR 0.6 million in 2006. This loss was due mainly to charges posted for interest swaps and currency hedging and to an increase in advance payment bond expenses owing to the greater number of projects in progress. Note, too, that in 2006 acquisition of CISBIO had a positive impact of EUR 1.4 million.

TAXES

Tax figures for 2007 show tax income of EUR 7.0 million, compared to EUR 7.8 million for the same period in 2006. This income was due to partial recognition of additional deferred tax assets following periodic analysis of the probability of future use, partially offset by tax expense in the countries in which the Company did not have useable deferred tax losses.

PROFIT (LOSS) FROM ENTITIES ACCOUNTED FOR UNDER THE EQUITY METHOD

This heading, which shows a profit of EUR 0.3 million, reflects the profits and losses of the various companies such as CISBIO in which IBA is a minority stakeholder with a “significant influence” according to IFRS.

NET INCOME

Net income totaled EUR 13.9 million in 2007, compared with exceptionally high earnings of EUR 30.0 for the same period in 2006, which include EUR 24.7 million from nonrecurring elements of the deal with Schering and the reversal of tax provisions.

DIVIDEND

The Board of Directors has decided to ask the shareholders to approve payment of a dividend of EUR 0.17 per share—the first in the history of the Company—at the Ordinary General Meeting of May 14, 2008.

EVENTS SUBSEQUENT TO THE END OF THE REPORTING PERIOD

There have been no significant events.

OTHER ITEMS

CALENDAR

2008 General Meeting	May 14, 2008, 10:00 AM
Announcement of results for six-month period ended June 30, 2008	August 29, 2008
Announcement of results for year ended December 31, 2008	March 5, 2009

**REPORT OF THE AUDITOR ON THE ACCOUNTING INFORMATION
IN THE ANNUAL COMMUNIQUÉ OF ION BEAM APPLICATIONS S.A.**

To the Board of Directors of Ion Beam Applications SA


We have not yet delivered our audit report on the annual consolidated accounts of your company for the year ended 31 December 2007. We confirm that our audit work has not revealed any significant matters requiring adjustments to the accounting information included in this press release.

In compliance with article 8, §6, 2nd part of the Royal Decree of 31 March 2003 concerning the duties of an issuer of financial instruments admitted on a Belgian regulated market, you have to include the following information in the annual press release:

"The auditor has confirmed that his audit work has not revealed any significant matters requiring adjustments to the accounting information included in this press release."

Brussels, 4 march 2008

Ernst & Young Reviseurs d'Entreprises SCC
Commissaire
Represented by



Eric Golenvaux
Partner



Press Release |

OUTLOOK

Looking to 2008, the company reiterates its confidence that, at constant exchange rates, it will be able to generate growing recurring earnings compared to those for 2007 while continuing its policy of investing in both R&D and sales and marketing.

It bases its confidence on the following:

1. Equipment orders of EUR 216 million at December 31, 2007, plus near-term prospects for finalizing several contracts
2. Predicted growth of the PET radiopharmaceutical market, particularly for FDG, and integration of CISBIO operations into the Group by midyear 2008.
3. New areas of application for electron accelerator technology
4. Positive outlook for Dosimetry in general and COMPASS in particular

ABOUT IBA

IBA delivers solutions of exceptional precision in the fields of cancer diagnosis and therapy. The company also provides sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT and belongs to the BelMid index.

Website: <http://www.iba-worldwide.com>.

Contact

IBA

Paul-Emmanuel Goethals
Director, Corporate Business Development
& Investor Relations
Tel: +32 10 47 58 16
paul-emmanuel.goethals@iba-group.com



Press Release |

CONSOLIDATED INCOME STATEMENT

	31/12/07	31/12/06	Variation	
	(EUR '000)	(EUR '000)	(EUR '000)	%
Sales and contract revenue	213,849	170,257	43,592	25.6%
Cost of sales and contract costs	144,004	116,912	27,092	23.2%
Gross profit	69,845	53,345	16,500	30.9%
	32.7%	31.3%		
Selling and marketing expenses	21,105	15,815	5,290	33.4%
General and administrative expenses	19,785	17,733	2,052	11.6%
Research and development expenses	17,167	10,028	7,139	71.2%
Recurring expenses	58,057	43,576	14,481	33.2%
Recurring profit	11,788	9,769	2,019	20.7%
Other non-recurring (income)/ expenses - net	4,748	-10,442	15,190	-145.5%
Finance (income)/ expenses - net	456	-593	1,049	-176.9%
Profit before tax	6,584	20,804	-14,220	-68.4%
Tax expense	-6,983	-7,826	843	-10.8%
Profit/ (loss) for the period from continuing operations	13,567	28,630	-15,063	-52.6%
Profit/ (loss) for the period from discontinued operations	1	-1,524	1,525	-100.1%
Share of profit/(loss) of equity-accounted companies	-278	2,882	-3,160	-109.6%
Profit for the period	13,846	29,988	-16,142	-53.8%
Minority interests	84	18		
Profit for the period	13,930	30,006		



Press Release |

CONSOLIDATED BALANCE SHEET

	31/12/07	31/12/06	
	(EUR '000)	(EUR '000)	
ASSETS			
Goodwill	26,538	28,100	-1,562
Other intangible assets	4,619	4,115	504
Property, plant and equipment	59,792	46,414	13,378
Investments accounted for using the equity method	8,381	8,304	77
Deferred tax assets	33,312	24,978	8,334
Other long-term receivables	18,641	8,789	9,852
Non-current assets	151,283	120,700	30,583
Inventories and contracts in progress	40,899	31,194	9,705
Accounts receivable	44,243	37,046	7,197
Other receivables	27,943	10,044	17,899
Derivative financial instruments Assets	1,860	284	1,576
Cash and cash equivalents	58,210	67,600	-9,390
Current assets	173,155	146,168	26,987
Total assets	324,438	266,868	57,570
EQUITY AND LIABILITIES			0
Share capital	36,215	35,747	468
Share premium	115,199	200,899	-85,700
Treasury shares	-6,746	-256	-6,490
Net gains on available-for-sales financial investments	0	658	-658
Hedging and other reserves	8,397	4,086	4,311
Cumulative translation differences	-12,309	-3,921	-8,388
Retained earnings	70	-101,386	101,456
Capital and reserves attributable to Company's equity holders	140,826	135,827	4,999
Minority interests	655	501	154
TOTAL EQUITY	141,481	136,328	5,153
Borrowings	17,854	18,156	-302
Deferred tax liabilities	369	225	144
Provisions	12,313	11,813	500
Other long-term liabilities	33,763	21,578	12,185
Non-current liabilities	64,299	51,772	12,527
Borrowings	8,328	5,448	2,880
Other short-term financial liabilities	0	0	0
Accounts payable	51,191	23,437	27,754
Current income tax liabilities	1,115	441	674
Other payables and accruals	58,024	49,442	8,582
Current liabilities	118,658	78,768	39,890
Total liabilities	182,957	130,540	52,417
Total equity and liabilities	324,438	266,868	57,570